WEBULL
WebtradeDownload

How Phase 3 Trial Progress At Novavax (NVAX) Has Changed Its Investment Story

Simply Wall St · 2d ago
  • Novavax reported that Sanofi Pasteur dosed the fifth participant in a European Phase 3 influenza COVID 19 combination vaccine trial, triggering a US$125 million milestone payment tied to Novavax's COVID 19 component.
  • The Sanofi collaboration gives Novavax a concrete cash inflow today, along with defined future milestones and potential royalties that directly support its partner focused, capital efficient operating model.
  • The focus now shifts to how Novavax's partner led investment narrative is shaped by this US$125 million Sanofi milestone trigger.

Compare Novavax's partner-led model with other potential breakout candidates by reviewing our hand picked 18 high quality undiscovered gems in similar high research, high-upside areas.

Novavax Investment Narrative Recap

To own Novavax, you need to believe its partner-led model turns a concentrated COVID 19 and respiratory portfolio into steadier milestone and royalty inflows. The firm also needs its lean cost base to translate those payments into a clearer path toward sustainable profitability. The Sanofi milestone meaningfully supports liquidity but does not remove funding and execution pressure.

The key near term swing factor is still commercial and regulatory progress for partnered respiratory vaccines, not this single US$125 million payment. The biggest risk remains reliance on partners hitting clinical, launch, and demand milestones on time, in a market where large vaccine players and alternative platforms compete hard for share.

The Sanofi Phase 3 milestone is closely tied to Novavax's most important catalyst, because the collaboration concentrates a large portion of future COVID flu and combination vaccine economics into one partner. You now have clearer visibility on near term cash inflow timing, plus defined manufacturing and launch milestones that could reshape the balance between cash burn and external funding needs.

Attention now turns to the mid 2027 manufacturing technology transfer milestone and the potential U.S. launch payment. Each step tests Sanofi's execution, regulatory outcomes, and market uptake assumptions. For you as a shareholder or prospective investor, the practical task is tracking whether these operational checkpoints arrive roughly when the company expects and how they interact with upcoming earnings trends.

What The Novavax Consensus Is Actually Pricing In

Analysts sketch a very different future profile for Novavax than the story implied by a single US$125 million milestone. Their models assume revenue declines by 31.4% per year over the next three years and profit margins compress from 39.2% today to 16.0% by 2028. That is a reset from a high earnings base toward a smaller, lower margin respiratory and partnership driven business.

The earnings bridge in those forecasts matters. Consensus points to earnings of US$55.9 million by 2028, compared with US$422.8 million today. That is a drop of roughly US$367 million in annual profit, even as analysts still assume Novavax supports a premium multiple and leans on a partner centric model to keep cash flow viable.

There is also wide dispersion in expectations. Some analysts think earnings could fall into a loss of up to US$145.1 million, which would mean royalties, milestones, and any residual COVID 19 product contribution fail to offset shrinking revenue and margin pressure. Others stay closer to the central case, where Novavax remains profitable but smaller and more tightly tied to partner execution than it is today.

Valuation work in these reports embeds that earnings path into a higher P/E assumption over time. The stock is framed as moving from about 2.8x current earnings to 46.2x on the 2028 consensus profit figure, a multiple that sits above the cited 15.5x for the broader US biotech group. For you as an investor, the key question is whether a partner led portfolio with shrinking sales and thinner margins deserves that kind of premium.

On revenue, the models anchor to a specific 2028 snapshot. Analysts expect Novavax to generate US$348.5 million of sales alongside that US$55.9 million of earnings in the same year. Those numbers imply a business that is materially smaller than today on the top line yet still earning positive profit, which hinges heavily on disciplined costs and a meaningful contribution from Sanofi and other collaborators.

The consensus price target of US$12.50, against a current share price around US$7.40, reflects that setup. Forecasts assume the underlying operation shrinks yet is still worth more than the market currently assigns, once you feed earnings, margins, and partner economics into their discount rate of about 6.9%. For any holder, the practical step is to stress test whether a 46.2x P/E on 2028 earnings and a sharply lower revenue base feels reasonable given the risks around trial timelines, regulatory decisions, and future vaccine demand.

Novavax's narrative projects US$348.5 million revenue and US$55.9 million earnings by 2028. This requires 31.4% yearly revenue decline and an earnings decrease of roughly US$367 million from US$422.8 million today.

Uncover how Novavax's fair value indicates a 32% potential upside to its current price that may not last much longer.

NasdaqGS:NVAX 1-Year Stock Price Chart
NasdaqGS:NVAX 1-Year Stock Price Chart

Exploring Other Perspectives

You are seeing two very different stories around Novavax. The bearish narrative leans hard on the risk that Matrix M royalties and milestones never quite catch up, with revenue assumptions around US$121.2 million and earnings of about US$19.3 million by 2029 before this Sanofi milestone was even on the radar. That cohort is effectively saying the business might remain small and expensive on a 78.3x P/E. Use this Sanofi trigger as a prompt to compare those assumptions with your own view and explore how fresh data could push future estimates in either direction.

Explore 3 other Novavax fair value estimates, including one that suggests it could be worth just $13.78!

Form Your Own Verdict

Don't just follow the ticker; dig into the data and build a conviction that's truly your own.

Looking For More Investment Ideas Beyond Novavax?

If you want to put Novavax in context and build a stronger watchlist, it can help to compare it with other stocks that fit clear, rules based criteria. The Simply Wall St Screener lets you scan for companies that line up with the kind of risk, balance sheet strength, or income profile you are actually comfortable owning.